Structure Therapeutics Inc.

For the period ended Sep 30, 2025. Filed Nov 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 6, 2025

GPCR$21.73+1.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Shareholders’ Equity

(IN THOUSANDS)


· · · · · · · · · · · · ·
· · · · · · · · · · ACCUMULATED · · · · · ·
· · ORDINARY · · ADDITIONAL · · OTHER · · · · · TOTAL
· · SHARES · · PAID-IN · · COMPREHENSIVE · · ACCUMULATED · · SHAREHOLDERS’
· SHARES · AMOUNT · CAPITAL · INCOME (LOSS) · DEFICIT · EQUITY
Balance at December 31, 2024	171,860	$17	$1,193,010	$914	$(329,098)	$864,843
Issuance of ordinary shares upon exercise of vested share options	644	—	965	—	—	965
Issuance of ordinary shares upon vesting of restricted share units	134	—	—	—	—	—
Shares withheld for taxes	(28)	—	(156)	—	—	(156)
Share-based compensation expense	—	—	5,918	—	—	5,918
Unrealized loss on investments, net	—	—	—	(99)	—	(99)
Net loss	—	—	—	—	(46,833)	(46,833)
Balance at March 31, 2025	172,610	17	1,199,737	815	(375,931)	824,638
Issuance of ordinary shares upon exercise of vested share options	22	—	43	—	—	43
Issuance of ordinary shares pursuant to employee share purchase plan	68	—	474	—	—	474
Depository issuance cost offset	—	—	1,531	—	—	1,531
Share-based compensation expense	—	—	7,509	—	—	7,509
Unrealized loss on investments, net	—	—	—	(453)	—	(453)
Net loss	—	—	—	—	(61,661)	(61,661)
Balance at June 30, 2025	172,700	17	1,209,294	362	(437,592)	772,081
Issuance of ordinary shares upon exercise of vested share options	95	—	377	—	—	377
Issuance of ordinary shares upon vesting of restricted share units	55	—	—	—	—	—
Issuance of ordinary shares upon vesting of performance share units	118		—
Shares withheld for taxes	(55)	—	(462)	—	—	(462)
Issuance of ordinary shares as part of ATM Offering, net of sales commission and offering expenses of $2,744	9,120	1	55,776	—	—	55,777
Share-based compensation expense	—	—	7,495	—	—	7,495
Unrealized gain on investments, net	—	—	—	463	—	463
Net loss	—	—	—	—	(65,712)	(65,712)
Balance at September 30, 2025	182,033	$18	$1,272,480	$825	$(503,304)	$770,019


· · · · · · · · · · · · ·
· · · · · · · · · · ACCUMULATED · · · · · ·
· · ORDINARY · · ADDITIONAL · · OTHER · · · · · TOTAL
· · SHARES · · PAID-IN · · COMPREHENSIVE · · ACCUMULATED · · SHAREHOLDERS’
· SHARES · AMOUNT · CAPITAL · INCOME (LOSS) · DEFICIT · EQUITY
Balance at December 31, 2023	139,220	$14	$659,003	$521	$(206,572)	$452,966
Issuance of ordinary shares upon exercise of vested share options	635	—	755	—	—	755
Share-based compensation expense	—	—	2,744	—	—	2,744
Unrealized loss on investments, net	—	—	—	(611)	—	(611)
Net loss	—	—	—	—	(26,036)	(26,036)
Balance at March 31, 2024	139,855	14	662,502	(90)	(232,608)	429,818
Issuance of ordinary shares upon Follow-On Offering, net of issuance costs and underwriting discounts of $34,688	31,281	3	512,727	—	—	512,730
Issuance of ordinary shares upon exercise of vested share options	427	—	478	—	—	478
Issuance of ordinary shares pursuant to employee share purchase plan	26	—	241	—	—	241
Share-based compensation expense	—	—	4,196	—	—	4,196
Unrealized loss on investments, net	—	—	—	(397)	—	(397)
Net loss	—	—	—	—	(26,034)	(26,034)
Balance at June 30, 2024	171,589	17	1,180,144	(487)	(258,642)	921,032
Issuance of ordinary shares upon exercise of vested share options	166	—	397	—	—	397
Issuance of ordinary shares upon vesting of restricted share units	7	—	—	—	—	—
Share-based compensation expense	—	—	6,023	—	—	6,023
Unrealized gain on investments, net	—	—	—	3,326	—	3,326
Net loss	—	—	—	—	(33,977)	(33,977)
Balance at September 30, 2024	171,762	$17	$1,186,564	$2,839	$(292,619)	$896,801

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.